ES8400667A1 - "procedimiento para la preparacion de una forma retardada debroxhexina, consistente en particulas esferoidales o tabletas dotadas de un recubrimiento". - Google Patents

"procedimiento para la preparacion de una forma retardada debroxhexina, consistente en particulas esferoidales o tabletas dotadas de un recubrimiento".

Info

Publication number
ES8400667A1
ES8400667A1 ES513754A ES513754A ES8400667A1 ES 8400667 A1 ES8400667 A1 ES 8400667A1 ES 513754 A ES513754 A ES 513754A ES 513754 A ES513754 A ES 513754A ES 8400667 A1 ES8400667 A1 ES 8400667A1
Authority
ES
Spain
Prior art keywords
acid
bromhexine
weight
percent
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES513754A
Other languages
English (en)
Other versions
ES513754A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of ES513754A0 publication Critical patent/ES513754A0/es
Publication of ES8400667A1 publication Critical patent/ES8400667A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PREPARACION DE UNA FORMA RETARDADA DE BROMHEXINA, CONSISTENTE EN PARTICULAS ESFEROIDALES O TABLETAS DOTADAS DE UN RECUBRIMIENTO. SE VENCE LA INSOLUBILIDAD DE LA BROMHEXINA AL PH MAS ELEVADO DEL TRACTO INTESTINAL MEDIANTE LA ADICION DE SUSTANCIAS DE ACCION ACIDA. LAS DIVERSAS FORMAS DE ESTE PREPARADO FARMACEUTICO SE REVISTEN CON UNA MEMBRANA QUE MUESTRA, POR UNA PARTE, UNA CARACTERISTICA DE LIBERACION ESPECIALMENTE ADAPTADA PARA LA BROMHEXINA PERO, POR OTRA PARTE, RETIENE DURANTE UN TIEMPO SUFICIENTEMENTE LARGO DENTRO DE LA FORMA FARMACEUTICA TAMBIEN LAS SUSTANCIAS ACIDAS QUE NORMALMENTE SE DISUELVEN MUCHO MAS RAPIDAMENTE. LA MEMBRANA ESTA CONSTITUIDA ESENCIALMENTE POR BARNICES INSOLUBLES EN ACIDOS PERO SOLUBLES EN EL JUGO INTESTINAL.
ES513754A 1981-07-07 1982-07-06 "procedimiento para la preparacion de una forma retardada debroxhexina, consistente en particulas esferoidales o tabletas dotadas de un recubrimiento". Expired ES8400667A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813126703 DE3126703A1 (de) 1981-07-07 1981-07-07 Bromhexin-retardform und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
ES513754A0 ES513754A0 (es) 1983-11-01
ES8400667A1 true ES8400667A1 (es) 1983-11-01

Family

ID=6136275

Family Applications (1)

Application Number Title Priority Date Filing Date
ES513754A Expired ES8400667A1 (es) 1981-07-07 1982-07-06 "procedimiento para la preparacion de una forma retardada debroxhexina, consistente en particulas esferoidales o tabletas dotadas de un recubrimiento".

Country Status (24)

Country Link
US (1) US4438091A (es)
EP (1) EP0069259B1 (es)
JP (1) JPS5859916A (es)
KR (1) KR880001753B1 (es)
AR (1) AR229183A1 (es)
AT (1) ATE11106T1 (es)
AU (1) AU556917B2 (es)
CA (1) CA1205384A (es)
CS (1) CS244909B2 (es)
DE (2) DE3126703A1 (es)
DK (1) DK163171C (es)
ES (1) ES8400667A1 (es)
FI (1) FI822375L (es)
GB (1) GB2101485B (es)
GR (1) GR76850B (es)
HU (1) HU186538B (es)
IE (1) IE53803B1 (es)
IL (1) IL66224A (es)
NO (1) NO159061C (es)
NZ (1) NZ201182A (es)
PH (1) PH20651A (es)
PL (1) PL142312B1 (es)
PT (1) PT75198B (es)
ZA (1) ZA824786B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
AU574360B2 (en) * 1983-05-13 1988-07-07 Reichert, D. Antisnoring agent
DE3317558A1 (de) * 1983-05-13 1984-11-15 Dietrich Dr.med. Sta. Eulalia Ibiza Reichert Orales antischnarchmittel
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
DE3524003A1 (de) 1985-07-04 1987-01-08 Heumann Ludwig & Co Gmbh Arzneimittelgranulat mit verzoegerter wirkstofffreisetzung und verfahren zu seiner herstellung
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
NZ242806A (en) * 1991-05-20 1994-01-26 Marion Laboratories Inc Multi-layered acid-containing coated drug beads.
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US5332727A (en) * 1993-04-29 1994-07-26 Birkmayer U.S.A. Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
JP3149125B2 (ja) * 1995-05-01 2001-03-26 信越化学工業株式会社 固形腸溶製剤のコーティング用基剤
WO2000018396A1 (fr) * 1998-09-25 2000-04-06 Sankyo Company, Limited PREPARATIONS A BASE D'INHIBITEUR DE HMG-CoA
JP2000159692A (ja) * 1998-09-25 2000-06-13 Sankyo Co Ltd ＨＭＧ―ＣｏＡレダクタ―ゼ阻害薬含有製剤
US6319332B1 (en) 1999-06-11 2001-11-20 James Albert Gavney, Jr. Squeegee device and system
CA2383220C (en) 1999-09-02 2009-11-03 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
JP3866715B2 (ja) * 2002-03-07 2007-01-10 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステル及びその塩の経口適用の投与形態
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
US20050053669A1 (en) * 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
DE10341414A1 (de) * 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
DE102004023930A1 (de) * 2004-05-12 2005-12-08 Boehringer Ingelheim Vetmedica Gmbh Schnell lösliches Granulat von Bromhexin/Bromhexinhydrochlorid, Verfahren zu dessen Herstellung und dessen Verwendung
RU2403033C2 (ru) 2005-03-22 2010-11-10 Лозан Фарма Гмбх Солюбилизированный ибупрофен
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
WO2007090082A2 (en) * 2006-01-27 2007-08-09 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US8679541B2 (en) * 2007-03-14 2014-03-25 Particle Dynamics International, Llc Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
US8377474B2 (en) 2007-12-28 2013-02-19 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20110144673A1 (en) 2009-12-11 2011-06-16 Fox Hollow Technologies, Inc. Material removal device having improved material capture efficiency and methods of use
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105640909B (zh) * 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2971889A (en) 1958-03-18 1961-02-14 Smith Kline French Lab Press coated enteric tablets and process for preparing them
US2928770A (en) 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
NL285698A (es) * 1961-11-20 1900-01-01
US3247066A (en) 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
NL297631A (es) 1963-06-03
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2031871C3 (de) 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
CA952431A (en) * 1970-09-28 1974-08-06 Frank M. Bardani Controlled release medicament
GB1468172A (en) 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DE2416142A1 (de) * 1974-04-03 1975-10-16 Thomae Gmbh Dr K Antiulcus-mittel
DD146547A5 (de) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
EP0069259B1 (de) 1985-01-09
KR880001753B1 (ko) 1988-09-12
EP0069259A3 (en) 1983-06-15
FI822375L (fi) 1983-01-08
NZ201182A (en) 1985-09-13
DK163171B (da) 1992-02-03
AU556917B2 (en) 1986-11-27
EP0069259A2 (de) 1983-01-12
IE821626L (en) 1983-01-07
GB2101485A (en) 1983-01-19
PH20651A (en) 1987-03-16
PL142312B1 (en) 1987-10-31
PT75198A (de) 1982-08-01
DE3261839D1 (en) 1985-02-21
CS516382A2 (en) 1985-09-17
FI822375A0 (fi) 1982-07-05
CA1205384A (en) 1986-06-03
HU186538B (en) 1985-08-28
US4438091A (en) 1984-03-20
PT75198B (de) 1985-10-04
IE53803B1 (en) 1989-03-01
DK303682A (da) 1983-01-08
ES513754A0 (es) 1983-11-01
AR229183A1 (es) 1983-06-30
ATE11106T1 (de) 1985-01-15
ZA824786B (en) 1984-03-28
IL66224A0 (en) 1982-11-30
CS244909B2 (en) 1986-08-14
JPS5859916A (ja) 1983-04-09
GR76850B (es) 1984-09-04
DK163171C (da) 1992-06-22
NO822216L (no) 1983-01-10
IL66224A (en) 1986-02-28
KR840000230A (ko) 1984-02-18
NO159061B (no) 1988-08-22
NO159061C (no) 1988-11-30
DE3126703A1 (de) 1983-01-27
AU8564682A (en) 1983-01-13
GB2101485B (en) 1984-10-03
PL237305A1 (en) 1985-05-07

Similar Documents

Publication Publication Date Title
ES8400667A1 (es) "procedimiento para la preparacion de una forma retardada debroxhexina, consistente en particulas esferoidales o tabletas dotadas de un recubrimiento".
IE810040L (en) Dipyridamole sustained release formulation
DE3571393D1 (en) Coating for pharmaceutical compositions
WO2000004875A3 (en) Preparation of aqueous clear solution dosage forms with bile acids
EP0339237A3 (en) Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them
IE821453L (en) Oral dipyridamole preparations
MY107277A (en) Thixotropic binder systems for thixotropic coating compositions.
DE3374686D1 (en) 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
ES8106705A1 (es) Procedimiento para la preparacion de derivados de aminoaci- dos
HK1010335A1 (en) Pellets
EP0393494A3 (en) Bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
IE42840L (en) Flameproofing composition
GB1506217A (en) Oral antilipemic composition
ES8100015A1 (es) Procedimiento para la preparacion de nuevos derivados de 2-(4-aminopiperidino)-3,4-dihidroquinoleina.
ATE44035T1 (de) Derivate des neocarzinostatins und verfahren zu deren herstellung.
IE873144L (en) Substituted thienoimidazole-toluidine derivatives, a process¹for their preparation, pharmaceutical compositions¹containing them, and their use as inhibitors of gastric acid¹secretion
GB1361779A (en) Vincamine salt and its use as a pharmaceutical composition
GB1289039A (es)
JPS55158937A (en) Polyester film
IE36030B1 (en) Anti-inflammatory preparations
JPS51130458A (en) Flame retardant polyamide resin compositions
KR830004842A (ko) 디피리서다몰 서방출형 제제의 제조방법
JPS5787411A (en) Aqueous solution of novel modified resin and its preparation
JPS5249263A (en) Flame-retarded polyamide resin compositions
GB1477791A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970519